Featured · metabolic
Retatrutide: A Research Guide to the GLP-1 / GIP / Glucagon Triple Agonist
TL;DR — Retatrutide is a single-molecule triple agonist of GLP-1, GIP, and glucagon receptors. In published trials it produced larger metabolic and body-composition shifts than dual-agonist or single-agonist research peptides over the same study window. Common research dose ranges run 1–6 mg weekly, typically titrated up.
Retatrutide is the leading triple-agonist research peptide, hitting GLP-1, GIP, and glucagon receptors at once. This guide covers what the literature says about mechanism, common research dosing ranges, observed effects, and how it differs from semaglutide and tirzepatide.
June 4, 2026 · 9 min
ZORVYN